5-酮基avermectin基因工程菌的构建  

The studies on the genetic engineered strain producing 5-O-avermectins

作　　者：马颖谡[1] 何建勇[1] 张怡轩[1] 

机构地区：[1]沈阳药科大学生命科学与生物制药学院,沈阳110016

出　　处：《中国抗生素杂志》2008年第3期148-152,共5页Chinese Journal of Antibiotics

基　　金：辽宁省企业博士后项目(辽博函2006-4);中国博士后项目(编号20070410356)

摘　　要：采用基因插入失活的方法,将1.5kb安普霉素抗性基因插入1.8kb aveF基因内部SalI位点,构建重组质粒pPC-5,并转化除虫链霉菌D2-14,获得基因工程菌株AV-F1。经HPLC分析,发现该菌株主要产生两个组分,分别为5-酮avermectin 1a和5-酮avermectin 2a,还产生一个小组分为acermectin B1a。5-酮avermectin基因工程菌株的构建成功,为化学合成新的avermectin衍生物提供了可利用的原料来源。Using the strategy of gene insert disruption, a 1.5 kb apramycin resistance gene fragment was inserted into the SalI site within the aveF gene, As a result, the recombinant disruption plasmid pPC-5 was constructed. The plasmid pPC-5 was transferred into the Streptomyces avermitilis D2-14 to obtain recombinant strain AV-F1. The products of strain AV-F1 by HPLC showed mainly two components, which were 5-O-avermectin la and 5-O-avermectin 2a, respectively. Moreover, it produced a small amount of avermectin Bla. The recombinant 5-O-avermectins producing strain AV-F1 could provide available material for chemical synthesis of new avermectins derivatives.

关 键 词：除虫链霉菌 AVERMECTIN 5-酮avermectin 基因失活 

分 类 号：R978.1[医药卫生—药品]